新型生物标志物可早期灵敏检测顺铂所致肾损伤
这项前瞻性探索性观察研究纳入105例接受顺铂(>65 mg/m2/周期)的癌症患者、20例非顺铂癌症对照和34例健康对照,比较新型尿液和血清生物标志物与标准标志物对顺铂药物性肾损伤(DIKI)的检测准确性。结果显示所有尿液新型标志物较非顺铂癌症对照有显著基线百分比变化,多数准确检测顺铂暴露(AUROC>0.8)且峰值更早;第二阶段裁定DIKI发生率增加41%,多数标志物AUROC>0.80,新型标志物可识别标准AKI标准未发现的亚临床DIKI。
要点
- 新型尿液标志物较标准标志物更早达峰,多数AUROC>0.8。
- 第二阶段裁定DIKI发生率增加41%,识别亚临床DIKI。
- 标准功能标志物可能低估顺铂相关肾损伤的真实发生率。
核心结论
- 新型生物标志物能准确及时检测顺铂暴露并识别标准AKI标准未发现的亚临床DIKI。
- 当前功能标志物在估计真实DIKI发生率方面存在局限性。
研究设计与样本
- 前瞻性探索性观察研究,纳入105例接受顺铂(>65 mg/m2/周期)的癌症患者、20例非顺铂癌症对照和34例健康对照。
- 治疗组于给药前、12小时后及第1、2、4、7、14、21天采集血清和尿液样本。
- 测量标准标志物和新型标志物(8种尿液、1种血清),比较准确性、基线百分比变化和至峰值中位时间。
- 对治疗组标志物谱进行两阶段盲法裁定以诊断DIKI。
主要发现
- 所有尿液新型标志物在治疗组较非顺铂癌症对照组有显著基线百分比变化,多数准确检测顺铂暴露(AUROC>0.8)。
- 新型标志物峰值出现更早。
- 第一阶段裁定(基于标准标志物)中,除中性粒细胞明胶酶相关脂质运载蛋白(NGAL)和胱抑素C(CYSC)外,尿液新型标志物的基线百分比变化在DIKI组(n=24)与无DIKI组(n=71)间无差异。
- 无论第一阶段裁定结果如何,治疗组所有标志物的基线百分比变化均大于对照组。
- 第二阶段裁定(标准+新型标志物)DIKI发生例数增至63例,发生率增加41%,多数标志物较非顺铂癌症对照AUROC>0.80。
临床怎么用
- 新型尿液和血清标志物可用于顺铂治疗患者的早期肾损伤监测,较标准标志物更早发现亚临床DIKI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We evaluated a panel of novel urinary and serum biomarkers (BMs) for early and sensitive detection of cisplatin drug-induced kidney injury (DIKI) in patients with cancer, comparing their diagnostic accuracy with standard BMs (SBMs). METHODS: In this prospective exploratory observational study, 105 patients treated with cisplatin ("treated" with > 65 mg/m2/cycle), 20 non-cisplatin treated cancer controls ("nontreated"), and 34 "healthy" controls were enrolled. The treated group's serum and urine samples were collected predose, after 12 hours, and on days 1, 2, 4, 7, 14, and 21. SBMs and novel BMs (NBMs; 8 urinary, 1 serum) were measured, comparing accuracy, percent changes from baseline (PCFBs), and median time to peak values between treated patients and nontreated cancer controls. Blinded adjudication of the treated group's BM profiles occurred at 2 stages for DIKI diagnosis. RESULTS: All urinary NBMs had significant PCFBs in the treated group compared with the nontreated cancer control group; most accurately detected cisplatin exposure (area under the receiver operating characteristics [ROC] curve [AUROC] > 0.8). NBMs peaked earlier. In stage 1 adjudication (SBMs) of the treated group, PCFB of urinary NBMs showed no difference between DIKI (n = 24) and no-DIKI (n = 71) groups except for neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C (CYSC). In treated participants, all BMs showed greater PCFBs than control groups, regardless of stage 1 DIKI adjudication. Stage 2 (SBMs and NBMs), DIKI incidence (n = 63) increased by 41%, with most BMs having an AUROC > 0.80 compared with the nontreated cancer control group. CONCLUSION: NBMs accurately and timely detected cisplatin exposure and identified "sub-clinical" DIKI undetected by standard acute kidney injury (AKI) criteria, highlighting the limitations of current functional BMs in estimating the true DIKI incidence.
引用
- Strader M, Friedman G, Benain X, et al. Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers. Kidney Int Rep. 2025. PMID: 40303198. doi:10.1016/j.ekir.2025.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。